Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher (PRV), striking a $180 million sale that reflects the high market demand for a speedy FDA review.

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...

The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies to treat depression and post-traumatic stress disorder (PTSD), the latest ...

Forbes contributors publish independent expert analyses and insights. Christine Ro is a journalist covering science and development. Occasionally I’ll go watch a TV show taping. Big-name shows are ...

Composition of Health Care Contact Days and Mortality Prediction Among Older Adult Clinical Trial Participants In this cross-sectional study, we used US Food and Drug Administration’s (FDA), European ...

Review Duration and Therapeutic Value of Cancer Drugs Granted Priority Versus Nonpriority Review in the United States, European Union, and Switzerland (2010-2024) Review Duration and Therapeutic Value ...

A Prescription Drug User Fee Act target date of September 27, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

Praxis Precision Medicines' New Drug Application for relutrigine will receive priority review by the Food and Drug Administration. The clinical-stage biopharmaceutical company said Monday that the FDA ...

AstraZeneca PLC (NYSE:AZN) is one of Goldman Sachs top healthcare stocks. On March 9, AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo secured Priority Review in the US for Enhertu, their candidate drug ...

If superior color accuracy and clear visual effects are your requirement, this 16-inch 3K OLED offers you a lot of top spec for such a portable display. The UPerfect UColor O2 is a second extended ...

Priovant Therapeutics, a company backed by Pfizer (PFE) and Roivant Sciences (ROIV), announced on Tuesday that the U.S. FDA has granted priority review for its marketing application targeted at its ...

FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026 Priority Review supported by positive Phase 3 VALOR results, the first ...